Anti-infective agents
    9.
    发明授权
    Anti-infective agents 有权
    抗感染剂

    公开(公告)号:US07951800B2

    公开(公告)日:2011-05-31

    申请号:US12613607

    申请日:2009-11-06

    CPC分类号: C07D495/04

    摘要: The present invention provides HCV polymerase inhibiting compounds having the formula (I): where R1 is cyclobutyl-N(Ra)—, n is 1, 2, 3 or 4, and at least one R5 is RaSO2N(Rj)alkyl-. In a non-limiting example, a compound of the present invention is N-[(3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin-3-yl}-1,1-dioxo-1,4-dihydro-1λ6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methanesulfonamide. The present invention also features compositions comprising the compounds of the present invention or pharmaceutically acceptable salts, stereoisomers or tautomers thereof, and methods of using the same to treat or prevent HCV infection.

    摘要翻译: 本发明提供了具有式(I)的HCV聚合酶抑制化合物:其中R1是环丁基-N(Ra) - ,n是1,2,3或4,并且至少一个R5是RaSO2N(Rj)烷基 - 。 在非限制性实例中,本发明的化合物是N - [(3- {1 - [(环丁基)氨基] -4-羟基-2-氧代-1,2-二氢 - 喹啉-3-基} -1,1-二氧代-1,4-二氢-1λ6-噻吩并[2,3-e] [1,2,4]噻二嗪-7-基)甲基]甲磺酰胺。 本发明还特征在于包含本发明化合物或其药学上可接受的盐,立体异构体或互变异构体的组合物及其用于治疗或预防HCV感染的方法。

    Anti-Infective Agents
    10.
    发明申请
    Anti-Infective Agents 有权
    抗感染剂

    公开(公告)号:US20100120753A1

    公开(公告)日:2010-05-13

    申请号:US12613607

    申请日:2009-11-06

    CPC分类号: C07D495/04

    摘要: The present invention provides HCV polymerase inhibiting compounds having the formula (I): where R1 is cyclobutyl-N(Ra)—, n is 1, 2, 3 or 4, and at least one R5 is RaSO2N(Rj)alkyl-. In a non-limiting example, a compound of the present invention is N-[(3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin-3-yl}-1,1-dioxo-1,4-dihydro-1λ6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide. The present invention also features compositions comprising the compounds of the present invention or pharmaceutically acceptable salts, stereoisomers or tautomers thereof, and methods of using the same to treat or prevent HCV infection.

    摘要翻译: 本发明提供了具有式(I)的HCV聚合酶抑制化合物:其中R1是环丁基-N(Ra) - ,n是1,2,3或4,并且至少一个R5是RaSO2N(Rj)烷基 - 。 在非限制性实例中,本发明的化合物是N - [(3- {1 - [(环丁基)氨基] -4-羟基-2-氧代-1,2-二氢 - 喹啉-3-基} -1,1-二氧代-1,4-二氢-1λ6-噻吩并[2,3-e] [1,2,4]噻二嗪-7-基)甲基]甲磺酰胺。 本发明还特征在于包含本发明化合物或其药学上可接受的盐,立体异构体或互变异构体的组合物及其用于治疗或预防HCV感染的方法。